Topics
Bill Information
Summary
Bill Summary
Introduced June 12, 2025 by Sen. Bernie Sanders with six Democratic and independent cosponsors, S.2068 would ban direct-to-consumer advertising of prescription drugs. It amends the Federal Food, Drug, and Cosmetic Act to deem a drug misbranded if its manufacturer ran any consumer-targeted promotion (TV, radio, print, digital, or social media) in the prior 30 days. The ban covers all FDA-approved drugs and licensed biologics regardless of approval date and takes effect 30 days after enactment. The bill is pending in the Senate HELP Committee.
Why It Matters to MAHA
Ending pharmaceutical TV and social media ads is a core MAHA priority. Secretary Kennedy has long been an outspoken critic of these ads and has called for banning them outright. In September 2025, the FDA sent thousands of warning letters and about 100 cease-and-desist letters, but that effort stopped short of an outright ban. S.2068 would put a full ban into law, which lasts longer than agency action that a court or a future administration could undo. Drugmakers spent $10.8 billion on these ads in 2024. This is rare bipartisan common ground, but a bill led by Sanders will need Republican cosponsors to move.
Sponsors

Bernie Sanders
Independent Senator (US)

Angus King
Independent Senator (US)

Chris Murphy
Democratic Senator (US)

Peter Welch
Democratic Senator (US)

Jeff Merkley
Democratic Senator (US)

Dick Durbin
Democratic Senator (US)

Tammy Duckworth
Democratic Senator (US)